The group's principal activities were the production, sale and licensing of complex natural product pharmaceuticals. The group produced and sold paclitaxel, a naturally occurring chemotherapeutic anti-cancer agent found in certain species of yew, or taxus, trees. It also developed other anti-cancer agents and licenses novel genomic technologies for applications in human therapeutics and diagnostics and agrobiotechnology. The group primarily used its gene editing technology to develop the agents that specifically and precisely edit genes. The products were sold under the trade names anzatax (TM), biotaxtm and napro paclitaxel and are used for injection to treat breast, ovarian and non-small cell lung cancers. The group sold the analytical services group and discontinued and disposed generic injectable paclitaxel business in 2003 and currently conducts only research and development.
